We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breast Cancer Test Links Immune Hotspots to Better Survival

By LabMedica International staff writers
Posted on 15 Mar 2015
A new test has been developed that can predict the survival chances of women with breast cancer by analyzing images of hotspots where there has been an intense immune reaction to a tumor. More...


The test that combines automated histological image processing with methods of spatial statistics could assess whether a woman's immune system is holding a cancer at bay and pick out those who will need intensive treatment to combat their more aggressive disease.

Scientists at The Institute of Cancer Research (London, UK) and their colleagues analyzed tumor samples from 245 women with a type of breast cancer called estrogen receptor negative (ER negative), which is particularly hard to treat. The team split women with breast cancer into two groups based on the numbers of immune hotspots spots within their tumors.

The tumor sections were scanned using ScanScope TX Scanner (Aperio Technologies; Vista, CA, USA) with × 20 magnification and digitized for image analysis. Stained frozen tumor section images for 245 ER-negative breast cancer patients were analyzed using their automated cell classification pipeline CRImage. The cell classification and location data were used as input for Getis–Ord hotspot analysis to enable the automated detection of statistically significant spatial clusters.

The scientists found that images of hotspots where immune cells were spatially clustered together around breast cancer cells provided a better measure of immune response than simply the numbers of immune cells within a tumor. Women whose cancers had a high number of spots lived an average of 91 months before their cancer spread, compared with just 64 months for those with a low number of spots. The test is the first objective method of measuring the strength of a patient's immune response to their tumors. Its automated analysis could complement existing methods where pathologists examine tumor samples under the microscope to gain a sense of whether there is a strong immune response.

Yinyin Yuan, PhD, the team leader and senior author, said, “We have shown that to measure the strength of an immune response to a cancer, we need to assess not just how many immune cells there are, but whether these are clustered together into cancer-busting hotspots. By analyzing the complex ways in which the immune system interacts with cancer cells, we can split women with breast cancer into two groups, who might need different types of treatment.” The study was published on February 27, 2015, in the journal Modern Pathology.

Related Links:
The Institute of Cancer Research  
Aperio Technologies  



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.